K

Kyowa Kirin

Global specialty pharma focused on antibodies

Veeva Vault Architect

Full-Time
$185k - $200k/yr+ Annual bonus + Long-term incentive program
Senior, Expert
Bachelor's
Princeton, NJ, USA
HybridRequires up to 10% domestic and international travel.
IT OperationsEnterprise Applications

About the job

Requirements
  • A bachelor's degree or equivalent experience in computer science, information systems, engineering, or related fields is required.
  • At least 8 years of experience configuring, implementing, supporting, and operating Veeva Vault-based solutions is required.
  • Proven expertise across multiple functional domains, including Quality, Regulatory, Medical, Commercial, and/or Clinical, is required.
  • Hands-on experience with Veeva APIs, integration patterns, and data migration tools is required.
  • Knowledge of GxP compliance, validation practices, and regulated system requirements is required.
  • Experience with large-scale, global implementations is required.
  • Willingness to travel up to 10% domestically and internationally is required.
  • Ability to work in a global environment and adapt to diverse cultural norms, communication styles, time zones, holiday schedules, and management approaches is required.
Responsibilities
  • Develop end-to-end architecture for Veeva Vault applications, including Quality, RIM, Medical, and Commercial applications.
  • Translate business requirements into scalable, secure, and compliant Veeva Vault configurations.
  • Define data models, object structures, workflows, lifecycle states, and security models.
  • Establish integration patterns between Veeva Vault and enterprise systems such as ERP, LMS, MDM, and LIMS.
  • Create architectural standards, design documents, and technical specifications.
  • Serve as the subject matter expert for Veeva Vault capabilities, limitations, and best practices.
  • Guide configuration teams on Vault objects, metadata, workflows, and automation.
  • Evaluate new Vault features and releases and advise on adoption and impact.
  • Ensure alignment with GxP, 21 CFR Part 11, Annex 11, and other regulatory frameworks.
  • Lead technical workstreams during Vault implementations, migrations, and enhancements.
  • Oversee data migration strategies, mapping, cleansing, and validation.
  • Support test planning, execution, and defect resolution for configuration and integrations.
  • Partner with project managers to ensure delivery timelines and quality standards are met.
  • Architect and oversee integrations using native Veeva Vault Integrations, Veeva APIs, Vault Loader, and middleware tools across Vault and other applications.
  • Ensure adherence to data governance, master data strategies, and cross-system data flows.
  • Ensure data integrity, auditability, and traceability across the Vault ecosystem.
  • Work with business process owners to understand needs and translate them into technical solutions.
  • Collaborate with QA/SA, Compliance, Data Privacy, and Validation teams to ensure system readiness.
  • Provide technical guidance to internal teams and external implementation partners.
  • Establish monitoring, performance optimization, and support frameworks.
  • Develop documentation, standard operating procedures, and knowledge-transfer materials.
  • Support ongoing enhancements, change requests, and continuous improvement initiatives.
Desired Qualifications
  • Experience with middleware platforms such as MuleSoft and Informatica, and with Master Data Management concepts and solutions.
  • Veeva Vault certification(s).

About the company

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for its PreCheck Pilot Program on June 30, 2026.
  • Kyowa Kirin signed a U.S. access deal August 31, 2026, deferring Section 232 tariffs.
  • Pipeline remains active: KHK4951, OTL-203, and ziftomenib all advanced in 2026.

What critics are saying

  • Rocatinlimab died March 3, 2026 after Kaposi's sarcoma signals and trial termination.
  • Kyowa Kirin faces patent cliffs: major products lose protection in 2032 and 2033.
  • Sanford's $530 million build concentrates execution risk until FDA-ready production starts in 2027.

What makes Kyowa Kirin unique

  • Kyowa Kirin owns antibody, fermentation, and rare-disease manufacturing expertise since 1949.
  • The Sanford, North Carolina plant becomes its first U.S. biologics site, operational 2027.
  • Ziftomenib outside the U.S. gives Kyowa Kirin global AML rights through 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Hybrid Work Options
  • Pet Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

PR Newswire
Dec 15th, 2025
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors

/PRNewswire/ -- Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A...

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding